Current Appointments & Affiliations
Biostatistician, Principal
Duke Clinical Research Institute,
Institutes and Centers
Recent Publications
A plain language review of the ATTRibute-CM study: efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy.
Journal Article Future Cardiol · December 2025 Full text Link to item CiteCharacterization of serum phosphate levels over time with intravenous ferric carboxymaltose versus placebo as treatment for heart failure with reduced ejection fraction and iron deficiency: An exploratory prospective substudy from HEART-FID.
Journal Article Eur J Heart Fail · May 2025 AIMS: Ferric carboxymaltose (FCM) is guideline-recommended for iron deficiency (ID) in heart failure with reduced ejection fraction (HFrEF). Despite a well-established safety profile, the magnitude and clinical significance of FCM-induced hypophosphataemia ... Full text Link to item CiteEfficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy.
Journal Article N Engl J Med · January 11, 2024 BACKGROUND: Transthyretin amyloid cardiomyopathy is characterized by the deposition of misfolded monomeric transthyretin (TTR) in the heart. Acoramidis is a high-affinity TTR stabilizer that acts to inhibit dissociation of tetrameric TTR and leads to more ... Full text Link to item CiteRecent Grants
2/2 IMPRroving Outcomes in Vascular DisEase - Aortic Dissection (IMPROVE-AD)
ResearchBiostatistician Investigator · Awarded by National Institutes of Health · 2023 - 2030PROMISE Trial: SDCC
Clinical TrialSenior Statistician · Awarded by National Institutes of Health · 2009 - 2015View All Grants